Skip to main content
SpringerLink
Log in

Long Term Management of Liver Transplant Rejection in Children

  • Disease Management
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

The current management of hepatic allograft rejection after liver transplantation in children requires effective baseline immunosuppression to prevent rejection and rapid diagnosis and treatment to manage acute rejection episodes. The subsequent impact on chronic rejection is dependent on the combination of adequate prevention and the treatment of acute rejection.

Tacrolimus is a macrolide lactone that inhibits the signal transduction of interleukin-2 (IL-2) via calcineurin inhibition. Introduced in 1989, tacrolimus was first used in the salvage of refractory acute or chronic rejection under cyclosporin or to rescue patients with significant cyclosporin-related complications. The majority of paediatric transplant centres use a combination of steroids with tacrolimus as a basic immunosuppressant regimen following paediatric liver transplantation. This combination has allowed the acute cellular rejection-free rate to increase to between 30 and 60%, while lowering the rate of refractory rejection to less than 5%. Corticosteroid-resistant rejection is commonly treated with monoclonal (muromonab CD3) or polyclonal preparations. Although most episodes of acute cellular rejection occur during the first 6 weeks after liver transplant, the appearance of late acute liver allograft rejection must raise the question of noncompliance, especially in the adolescent population. Chronic rejection is becoming increasingly rare under tacrolimus-based immunosuppression. Tacrolimus is effective in reversing refractory acute cellular rejection or early chronic rejection in patients initially treated with cyclosporin-based regimens. Patients with a history of noncompliance as well as children with autoimmune liver disease are at risk of chronic rejection. Retransplantation therapy for chronic rejection has, fortunately, become more rare in the tacrolimus era with only 3% of retransplants being performed for this indication.

Newer immunosuppressive agents are further modifying the long term management of liver allograft rejection. These include mycophenolate mofetil, rapamycin and IL-2 antibodies such as daclizumab. The development of these agents is allowing patient-specific immunosuppressive management to minimise rejection as well as the complications related to immunosuppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Mazariegos GV, Reyes J. What’s new in pédiatric organ transplantation. Pediatr Rev 1999; 20 (11): 363–75

    PubMed  CAS  Google Scholar 

  2. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579

    Article  PubMed  CAS  Google Scholar 

  3. Starzl TE, Marchioro TL, Wadder WR, et al. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385–95

    PubMed  CAS  Google Scholar 

  4. Murray JE, Merril JP, Harrison JH, et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268: 1315–23

    Article  PubMed  CAS  Google Scholar 

  5. Calne RY, Rolles K, White DJG, et al. Cyclosporine A initially as the only immunosuppressant in 34 recipient of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; II: 1033–6

    Article  Google Scholar 

  6. Starzl TE, Todo S, Fung JJ, et al. FK 506 for liver, kidney and pancreas transplantation. Lancet 1989; II: 1000–4

    Article  Google Scholar 

  7. Fisher LR, Henley KS, Lucey MR. Acute cellular rejection after liver transplantation: variability, morbidity, and mortality. Liver Transplant Surg 1995; 1: 10–15

    Article  CAS  Google Scholar 

  8. Wiesner RH, Jemetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28: 638–44

    Article  PubMed  CAS  Google Scholar 

  9. Dousset B, Conti F, Cherruau B, et al. Is acute rejection deleterious to long-term liver allograft function? J Hepatol 1998; 29: 660–8

    Article  PubMed  CAS  Google Scholar 

  10. Freese DK, Snover DC, Sharp HL, et al. Chronic rejection after liver transplantation: a study of clinical, histopathological and immunological features. Hepatology 1991; 13: 882–90

    Article  PubMed  CAS  Google Scholar 

  11. Demetris AJ, Murase N, Lee RG, et al. Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant 1997; 2 (2): 27–44

    PubMed  CAS  Google Scholar 

  12. Starzl TE, Iwatuski S, Van Thiel DH, et al. Evolution of liver transplantation. Hepatology 1982; 3: 614–36

    Google Scholar 

  13. Hoyer PF. Cyclosporine A (Neoral®) in pediatric organ transplantation. Pediatr Transplant 1998: 2: 35–9

    PubMed  CAS  Google Scholar 

  14. Arumugum R, Soriano HE, Scheimann AO, et al. Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric livertransplant recipients. Clin Transplant 1998: 12: 588–92

    Google Scholar 

  15. Graziadei IW, Wiesner RH, Marotta PJ, et al. Neoral® compared to Sandimmune® is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation. Transplantation 1997; 64 (5): 726–31

    Article  PubMed  CAS  Google Scholar 

  16. Pollard SG, Lear PA, Ready AR, et al. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. Transplantation 1999; 68 (9): 1325–31

    Article  PubMed  CAS  Google Scholar 

  17. Alvarez F, Atkinson PR, Grant DR, et al. NOF-11: a one-year pediatric randomized double-blind comparison of Neoral® versus Sandimmune® in orthotopic liver transplantation. Transplantation 2000; 69 (1): 87–92

    Article  PubMed  CAS  Google Scholar 

  18. Fung JJ, Todo S, Jain A, et al. Conversion from cyclosporine to FK506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc 1990; 22: 6–12

    PubMed  CAS  Google Scholar 

  19. Jain A, Reyes J, Kashyap R, et al. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg 1999; 230 (3): 441–9

    Article  PubMed  CAS  Google Scholar 

  20. Manez R, Jain AB, Marino IR, et al. Comparative evaluation of tacrolimus (FK506) and cyclosporine A as immunosuppressive agents (review). Transplant Review 1995; 9: 63–76

    Article  Google Scholar 

  21. Inomata Y, Tanaka K, Egawa H, et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation 1996; 61: 247–52

    Article  PubMed  CAS  Google Scholar 

  22. Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996; 61: 1188–92

    Article  PubMed  CAS  Google Scholar 

  23. Fisher RA, Ham JM, Marcos A, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998; 66: 1616–21

    Article  PubMed  CAS  Google Scholar 

  24. Jain AB, Hamad I, Rakela J, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation 1998; 66: 1395–8

    Article  PubMed  CAS  Google Scholar 

  25. Renz JF, Lightdale J, Mudge C, et al. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Liver Transpl Surg 1999; 5 (2): 136–43

    Article  PubMed  CAS  Google Scholar 

  26. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31 (5): 335–40

    Article  PubMed  CAS  Google Scholar 

  27. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation. 1998; 66 (8): 1040–6

    Article  PubMed  CAS  Google Scholar 

  28. Kahan BD. Pivotal phase III multicenter, randomized, blinded trial of sirolimus versus azathioprine in combination with cyclosporine and prednisone in primary renal transplants [abstract]. 25th Annual Scientific Meeting of the American Society of Transplantation; 1999 May 15–19; Chicago

  29. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group [see comments]. Comment in: Transplantation 1999 Apr 15; 67 (7): 937–8. Transplantation 1999; 67 (7): 1036-42

    Google Scholar 

  30. Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67 (4): 505–9

    Article  PubMed  CAS  Google Scholar 

  31. McAlister VC, Gao Zuhua, Peltekian K, et al. Sirolimustacrolimus combination immunosuppression. Lancet 2000; 335: 376–7

    Article  Google Scholar 

  32. Kahan BD. The potential role of rapamycin in pediatric transplantation as observed from adult studies. Pediatr Transplant 1999; 3: 175–80

    Article  PubMed  CAS  Google Scholar 

  33. Brown PS, Parenteau GL, Dirbas FM, et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc Natl Acad Sci U S A 1991; 88: 2663–7

    Article  PubMed  CAS  Google Scholar 

  34. Kahan BD, Rajagopalan RP, Hall ML, et al, US Simulect® Study Group. Basiliximab (Simulect®) is efficacious in reducing the incidence of acute rejection episodes in renal allograft patients: results at 12 months [abstract 748]. Program and abstracts of the 17th Annual Meeting of the American Society of Transplant Physicians; 1998 May 9–13; Chicago

  35. Nashan B, Moore R, Amlot P, et al. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193–8

    Article  PubMed  CAS  Google Scholar 

  36. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338 (3): 161–5

    Article  PubMed  CAS  Google Scholar 

  37. Zenapax Double and Triple Therapy Study Groups. Pooled analysis of phase III studies of Zenapax® (daclizumab), a humanized anti-IL-2R antibody [abstract 712]. Program and abstracts of the 17th Annual Meeting of the American Society of Transplant Physicians; 1998 May 9–13; Chicago

  38. Ettenger RB, Antibody therapy as an induction regimen in pediatric renal transplantation. Transplant Proc 1999; 31: 2676–8

    Article  Google Scholar 

  39. Fung JJ, Eliasziw M, Todo S, et al. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996; 183: 117–24

    PubMed  CAS  Google Scholar 

  40. Neuhaus P, Bechstein WO, Blumhardt G, et al. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423–8

    Article  Google Scholar 

  41. Busuttil RW, McDiarmid S, Klintmalm GB, et al. Acomparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331: 1110–5

    Article  Google Scholar 

  42. Jain A, Khanna A, Molmenti E, et al. Immunosuppressive therapy: new concepts. Surg Clin NA 1999; 79 (1): 59–76

    Article  CAS  Google Scholar 

  43. Weisner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation. Transplantation 1998; 66: 493–9

    Article  Google Scholar 

  44. McDiarmid SV, Busutil RW, Ascher NL, et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. multicenter trial. Transplantation 1995; 59 (4): 530–6

    PubMed  CAS  Google Scholar 

  45. Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclosporine A and tacrolimus. Pediatr Transplant 1999; 3: 22–6

    Article  PubMed  CAS  Google Scholar 

  46. The Canadian Prograf in Liver Transplant Trial: the one year composite outcome [abstract]. Transplantation 1998; 65 Suppl. : S14

  47. Levy GA. Neoral®/cyclosporine-based immunosuppression. Liver Transpl Surg 1999; 54 Suppl. 1: S37–47

    Google Scholar 

  48. Rolles K, Davidson BR, Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation 1999; 68 (8): 1195–209

    Article  PubMed  CAS  Google Scholar 

  49. Boillot O, Viale JP, Gratadour P, et al. Reversal of early acute rejection with increased doses of tacrolimus in liver transplantation. Transplantation 1998; 66: 1182–5

    Article  PubMed  CAS  Google Scholar 

  50. Platz KP, Mueller AR, Zytowski M, et al. Management of acute steroid-resistant rejection after liver transplantation. World J Surg 1996; 20: 1052–9

    Article  PubMed  CAS  Google Scholar 

  51. Jain A, Mazariegos G, Kashyap R, et al. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation. Transplantation. In press

  52. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation 1998; 66: 29–37

    Article  PubMed  CAS  Google Scholar 

  53. Reggiani P, Gridelli B, Colledan M, et al. Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: experience in 20 children. Transpl Int 1998; 11 Suppl. 1: S272–4

    PubMed  Google Scholar 

  54. Jara P, Robledo MJ, Frauca E, et al. Tacrolimus for steroid-resistant liver rejection in children. Transpl Int 1998; 11 Suppl. 1: S275–7

    PubMed  Google Scholar 

  55. Herbert MF, Ascher NL, Lake JR, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67 (5): 707–12

    Article  Google Scholar 

  56. Seiler CA, Renner EL, Czerniak A, et al. Early acute cellular rejection: no effect on late hepatic allograft function in man. Transpl Int 1999; 12: 195–201

    Article  PubMed  CAS  Google Scholar 

  57. Anand AC, Hubscher SG, Gunson BK, et al. Timing, significance, and prognosis of late acute liver allograft rejection. Transplantation 1995; 60 (10): 1098–103

    Article  PubMed  CAS  Google Scholar 

  58. McDiarmid SV. The use of tacrolimus in pediatric liver transplantation. J Pediatr Gastroenterol Nutr 1998; 26: 90–102

    Article  PubMed  CAS  Google Scholar 

  59. Pappo O, Ramos H, Starzl TE, et al. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995; 19 (2): 192–206

    Article  PubMed  CAS  Google Scholar 

  60. Kosmach B, Webber SA, Reyes J. Care of the pediatric solid organ transplantation. Pediatric Clin North Am 1998; 45: 1395–417

    Article  CAS  Google Scholar 

  61. Molmenti E, Mazariegos G, Bueno J, et al. Noncompliance after pediatric liver transplantation. Transplant Proc 1999; 31 (1–2): 408

    Article  PubMed  CAS  Google Scholar 

  62. McDiarmid SV, Wallace P, Vargas, et al. The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 1995; 20: 291–9

    Article  PubMed  CAS  Google Scholar 

  63. Sher LS, Cosenza C, Michel J, et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation. Transplantation 1997; 64: 258–63

    Article  PubMed  CAS  Google Scholar 

  64. Reyes J, Jain A, Mazariegos G, et al. Long term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation. In press

  65. Nicolette LA, Reichard KW, Falkenstein K, et al. Results of transplantation for acute and chronic hepatic allograft rejection. J Pediatr Surg 1998; 33: 909–12

    Article  PubMed  CAS  Google Scholar 

  66. D’Alessandro AM, Rutger JP, Stuart JK, et al. Retransplantation of the liver — a seven-year experience. Transplantation 1993; 55: 1083–7

    Article  PubMed  Google Scholar 

  67. Khanna A, Jain A, Mieles L, et al. Liver retransplantation in children: study of 184 cases [abstract C78]. The 2nd International Congress on Pediatric Transplantation, Pediatr Nephrol; 1996 Aug 22-24; Paris

  68. Dvorchik I, Cacciarelli TV, Jain A, et al. Indications and results of hepatic retransplantation in children receiving primary tacrolimus therapy [abstract]. The Transplantation Society, XVII World Congress; 1998 Jul 12–17; Montreal: 214

  69. Goss JA, Shackleton CR, MacDiarmid SV, et al. Long-term results of pediatric liver transplantation. An analysis of 569 transplants. Ann Surg 1998; 228 (3): 411–20

    Article  PubMed  CAS  Google Scholar 

  70. Cacciarelli TV, Green M, Jaffe R, et al. Management of posttransplantation lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. Transplantation 1998; 66 (8): 1047–52

    Article  PubMed  CAS  Google Scholar 

  71. Newell KA, Alonso EM, Whitington PF, et al. Posttransplantation lymphoproliferative disease in pediatric liver transplantation. Transplantation 1996; 62 (3): 370–5

    Article  PubMed  CAS  Google Scholar 

  72. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58 (2): 170–8

    PubMed  CAS  Google Scholar 

  73. Bartosh SM, Thomas SE, Sutton MM, et al. Linear growth after pediatric liver transplantation. J Pediatr 1999; 135: 624–31

    Article  PubMed  CAS  Google Scholar 

  74. Schimmer BP, Parker KL. Adrenocorticotropic hormone, adrenal steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 9th ed. New York: The McGraw Hill Companies Inc., 1996: 1459–85

    Google Scholar 

  75. McDiarmid SV, Farmer DA, Goldstein LI, et al. A randomized prospective trial of steroid withdrawal after liver transplantation. Transplantation 1995; 60: 1443–50

    Article  PubMed  CAS  Google Scholar 

  76. McKee M, Mattei P, Schwarz K et al. Steroid withdrawal in tacrolimus (FK506)-treated pediatric liver transplant recipients. J Pediatr Surg 1997; 32 (7): 973–5

    Article  PubMed  CAS  Google Scholar 

  77. Stegall MD, Wachs ME, Everson G, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate. Transplantation 1997; 64: 1755–60

    Article  PubMed  CAS  Google Scholar 

  78. Reyes J, Zeevi A, Ramos H, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993; 25 (6): 3315–9

    PubMed  CAS  Google Scholar 

  79. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63: 243–9

    Article  PubMed  CAS  Google Scholar 

  80. Inomata Y, Takatsuki M, Uemoto S, et al. Weaning of immunosuppression in living-related liver transplantation [abstract]. Nihon Rinsho Meneki Kashi 1999; 22 (6): 431–5

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Thomas E. Starzl Transplantation Institute, and Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA

    George V. Mazariegos, Alcides A. Salzedas, Joseph Zavatsky, Rakesh Sindhi, Maria Parizhskaya, William McGhee, Ashok Jain & Jorge Reyes

Authors
  1. George V. Mazariegos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alcides A. Salzedas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph Zavatsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rakesh Sindhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Parizhskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. William McGhee
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ashok Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jorge Reyes
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George V. Mazariegos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazariegos, G.V., Salzedas, A.A., Zavatsky, J. et al. Long Term Management of Liver Transplant Rejection in Children. BioDrugs 14, 31–48 (2000). https://doi.org/10.2165/00063030-200014010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200014010-00004

Keywords

Search

Navigation